| Theme | The consideration of polypharmacy in dialysis patients | |
|---|---|---|
| Title | Antihypoglycemic medication in patients with diabetes undergoing dialysis | |
| Publish Date | 2017/04 | |
| Author | Noriko Yoshida | Diabetes Center, Tokyo Women's Medical University School of Medicine |
| Author | Naofumi Yoshida | Diabetes Center, Tokyo Women's Medical University School of Medicine |
| Author | Tetsuya Babazono | Diabetes Center, Tokyo Women's Medical University School of Medicine |
| [ Summary ] | Intensive insulin therapy is essential for patients with type 1 diabetes, regardless of whether they have chronic kidney disease. In patients with type 2 diabetes and end-stage renal disease who are undergoing dialysis, single or multiple hypoglycemic agents are selected from oral and injectable preparations. Seven oral drugs and 5 glucagon-like peptide (GLP)-1 receptor agonists are currently in the market in Japan.However, in patients on dialysis, oral drug options are limited to α-glucosidase inhibitors, fast-acting insulin secretagogues, and dipeptidyl peptidase 4 inhibitors ; whereas, GLP-1 receptor agonist choicesare limited to liraglutide, lixisenatide, and dulaglutide. The use of multiple hypoglycemic drugs or treatment with hypoglycemic drugs combined with medications that may cause hypoglycemia as a side effect may be associated with the risk of polypharmacy. | |